Solving the Medical Marketing Blues
A conversation with Reprints Desk's Scott Ahlberg, Head of Corporate Services, and Christian Gray, Business Development, about solving pharma's
Scientist vs Salesman: Which approach will enable your sales reps to raise their value...
A conversation with Tim Ryan, Executive Director of Prescription Medicines, Training, and Development at Boehringer Ingelheim, about his upcoming presentation/panel discussion at eyeforpharma's Sales Force Effectiveness USA 2010 conference on May 17-18 in Princeton, NJ.
Online Community Management: Moderation Best Practices & Other Tips for Pharma Social Media Managers
A conversation with Jenna Woodul, EVP, Chief Community Officer, LiveWorld, Inc., about how pharma companies can manage their social media interactions using technology and
What Sanofi-Aventis Learned from Its FaceBook Experience & What the Experts Recommend It Do...
A conversation with Dennis Urbaniak, VP U.S. Diabetes at sanofi-aventis, about the recent activity on S-A's VOICES corporate Facebook page. We'll discuss the lessons learned and hear advice from independent experts. Urbaniak is willing to answer questions and consider advice from listeners.
Teaching Pharma Social Marketing to Biotech Scientists
A conversation with Eric S. Langer, Adjunct Faculty Member, Johns Hopkins University, and President/Managing Partner of BioPlan Associates, Inc., about teaching
Reach & Teach Physicians with Virtual Reality: Viscira’s “EyeMAC” Wet AMD Simulation Exhibit
A conversation with Dave Gulezian, President and CEO of Viscira, about the use of virtual reality simulation to reach and teach physicians at medical conventions. Featured is his company's
Pharma’s Social Media Working Group: Who It Consists of, How It Formed, and What...
A conversation with Craig M. Audet, Vice-President and Head of the US Regulatory Affairs Marketed Products Group at sanofi-aventis, Mark Gaydos, Senior Director, U.S. Regulatory Affairs Marketed Products at sanofi-aventis, and Cynthia Phillips, Sr Dir Labeling and Promotional Compliance at Millennium Pharmaceuticals, about their views on how pharmaceutical companies should handle posts made on social media sites owned or sponsored by them. Of particular interest are posts that mention off-label indications or adverse events.
Is the M&A Frenzy Short-Circuiting Pharma R&D? A Former Researcher Speaks Out
A conversation with Kenneth 'Eric' Milgram, Ph.D., Principal, Applied Scientific Consulting, former Director, Systems Biology Technologies at Wyeth Pharmaceuticals/Pfizer, about what happens to pharmaceutical companies when they put Wall Street expectations ahead of science-driven innovation.
ACOR: An Online Social Networking Community of Cancer Patients & Caregivers Pharma Can’t Join...
A conversation with Gilles Frydman, founder of the Association of Online Cancer Resources, about how this venerable and vibrant online community has helped more than 600,000 cancer sufferers and caregivers for over 13 years!
Fear & Loathing in Washington, DC: Takeaways from the FDA Public Hearing
Speakers, attendees and ePharma Pioneer Club members discuss the key takeaways of FDA's November 12-13 public hearing on the use of social media by the pharmaceutical industry. What key points were made? What questions were asked by FDA? What are the next steps?
